Risk of Hormone Escape in a Human Prostate Cancer Model Depends on Therapy Modalities and Can Be Reduced by Tyrosine Kinase Inhibitors

Charlotte Guyader(Institut Curie), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris)

PLoS ONE

August 6, 2012

10.1371/journal.pone.0042252

Cited by 17

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2021|645

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

|Nature|2021|603

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

|The Lancet Oncology|2021|411

Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

|European Urology|2023|128